408 related articles for article (PubMed ID: 31104135)
1. Comparison of recent pivotal recommendations for the diagnosis and treatment of late-onset Pompe disease using diagnostic nodes-the Pompe disease burden scale.
Hundsberger T; Schoser B; Leupold D; Rösler KM; Putora PM
J Neurol; 2019 Aug; 266(8):2010-2017. PubMed ID: 31104135
[TBL] [Abstract][Full Text] [Related]
2. Pompe disease in Austria: clinical, genetic and epidemiological aspects.
Löscher WN; Huemer M; Stulnig TM; Simschitz P; Iglseder S; Eggers C; Moser H; Möslinger D; Freilinger M; Lagler F; Grinzinger S; Reichhardt M; Bittner RE; Schmidt WM; Lex U; Brunner-Krainz M; Quasthoff S; Wanschitz JV
J Neurol; 2018 Jan; 265(1):159-164. PubMed ID: 29181627
[TBL] [Abstract][Full Text] [Related]
3. 36-Months follow-up assessment after cessation and resuming of enzyme replacement therapy in late onset Pompe disease: data from the Swiss Pompe Registry.
Scheidegger O; Leupold D; Sauter R; Findling O; Rösler KM; Hundsberger T
J Neurol; 2018 Dec; 265(12):2783-2788. PubMed ID: 30232608
[TBL] [Abstract][Full Text] [Related]
4. Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD).
Ripolone M; Violano R; Ronchi D; Mondello S; Nascimbeni A; Colombo I; Fagiolari G; Bordoni A; Fortunato F; Lucchini V; Saredi S; Filosto M; Musumeci O; Tonin P; Mongini T; Previtali S; Morandi L; Angelini C; Mora M; Sandri M; Sciacco M; Toscano A; Comi GP; Moggio M
Neuropathol Appl Neurobiol; 2018 Aug; 44(5):449-462. PubMed ID: 28574618
[TBL] [Abstract][Full Text] [Related]
5. The emerging phenotype of late-onset Pompe disease: A systematic literature review.
Chan J; Desai AK; Kazi ZB; Corey K; Austin S; Hobson-Webb LD; Case LE; Jones HN; Kishnani PS
Mol Genet Metab; 2017 Mar; 120(3):163-172. PubMed ID: 28185884
[TBL] [Abstract][Full Text] [Related]
6. Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G "late-onset" GAA variant.
Rairikar MV; Case LE; Bailey LA; Kazi ZB; Desai AK; Berrier KL; Coats J; Gandy R; Quinones R; Kishnani PS
Mol Genet Metab; 2017 Nov; 122(3):99-107. PubMed ID: 28951071
[TBL] [Abstract][Full Text] [Related]
7. Effect of enzyme replacement therapy in late onset Pompe disease: open pilot study of 48 weeks follow-up.
Park JS; Kim HG; Shin JH; Choi YC; Kim DS
Neurol Sci; 2015 Apr; 36(4):599-605. PubMed ID: 25388776
[TBL] [Abstract][Full Text] [Related]
8. Improvement of bone mineral density after enzyme replacement therapy in Chinese late-onset Pompe disease patients.
Sheng B; Chu YP; Wong WT; Yau EKC; Chen SPL; Luk WH
BMC Res Notes; 2017 Jul; 10(1):351. PubMed ID: 28754168
[TBL] [Abstract][Full Text] [Related]
9. Swiss national guideline for reimbursement of enzyme replacement therapy in late-onset Pompe disease.
Hundsberger T; Rohrbach M; Kern L; Rösler KM
J Neurol; 2013 Sep; 260(9):2279-85. PubMed ID: 23749294
[TBL] [Abstract][Full Text] [Related]
10. Consensus treatment recommendations for late-onset Pompe disease.
Cupler EJ; Berger KI; Leshner RT; Wolfe GI; Han JJ; Barohn RJ; Kissel JT;
Muscle Nerve; 2012 Mar; 45(3):319-33. PubMed ID: 22173792
[TBL] [Abstract][Full Text] [Related]
11. Hypersensitivity infusion-associated reactions induced by enzyme replacement therapy in a cohort of patients with late-onset Pompe disease: An experience from the French Pompe Registry.
Lessard LER; Tard C; Salort-Campana E; Sacconi S; Béhin A; Bassez G; Orlikowski D; Merle P; Nollet S; Gallay L; Bérard F; Robinson P; Bouhour F; Laforêt P
Mol Genet Metab; 2023 Jul; 139(3):107611. PubMed ID: 37285781
[TBL] [Abstract][Full Text] [Related]
12. Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment.
Montagnese F; Barca E; Musumeci O; Mondello S; Migliorato A; Ciranni A; Rodolico C; De Filippi P; Danesino C; Toscano A
J Neurol; 2015; 262(4):968-78. PubMed ID: 25673129
[TBL] [Abstract][Full Text] [Related]
13. Muscle Proteomic Profile before and after Enzyme Replacement Therapy in Late-Onset Pompe Disease.
Moriggi M; Capitanio D; Torretta E; Barbacini P; Bragato C; Sartori P; Moggio M; Maggi L; Mora M; Gelfi C
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799647
[TBL] [Abstract][Full Text] [Related]
14. Cessation and resuming of alglucosidase alfa in Pompe disease: a retrospective analysis.
Hundsberger T; Rösler KM; Findling O
J Neurol; 2014 Sep; 261(9):1684-90. PubMed ID: 24923245
[TBL] [Abstract][Full Text] [Related]
15. A Comprehensive Update on Late-Onset Pompe Disease.
Labella B; Cotti Piccinelli S; Risi B; Caria F; Damioli S; Bertella E; Poli L; Padovani A; Filosto M
Biomolecules; 2023 Aug; 13(9):. PubMed ID: 37759679
[TBL] [Abstract][Full Text] [Related]
16. Observational clinical study of 22 adult-onset Pompe disease patients undergoing enzyme replacement therapy over 5years.
Stepien KM; Hendriksz CJ; Roberts M; Sharma R
Mol Genet Metab; 2016 Apr; 117(4):413-8. PubMed ID: 26873529
[TBL] [Abstract][Full Text] [Related]
17. White matter lesions in treated late onset Pompe disease are not different to matched controls.
Schneider I; Hensel O; Zierz S
Mol Genet Metab; 2019 Jun; 127(2):128-131. PubMed ID: 31153821
[TBL] [Abstract][Full Text] [Related]
18. Respiratory function during enzyme replacement therapy in late-onset Pompe disease: longitudinal course, prognostic factors, and the impact of time from diagnosis to treatment start.
Stockton DW; Kishnani P; van der Ploeg A; Llerena J; Boentert M; Roberts M; Byrne BJ; Araujo R; Maruti SS; Thibault N; Verhulst K; Berger KI
J Neurol; 2020 Oct; 267(10):3038-3053. PubMed ID: 32524257
[TBL] [Abstract][Full Text] [Related]
19. Effects of enzyme replacement therapy on bone density in late onset Pompe disease.
Avanti M; Martin A; Columbres RC; Mozaffar T; Kimonis V
Mol Genet Metab; 2023 Nov; 140(3):107644. PubMed ID: 37515933
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis and treatment of late-onset Pompe disease in the Middle East and North Africa region: consensus recommendations from an expert group.
; Al Jasmi F; Al Jumah M; Alqarni F; Al-Sanna'a N; Al-Sharif F; Bohlega S; Cupler EJ; Fathalla W; Hamdan MA; Makhseed N; Nafissi S; Nilipour Y; Selim L; Shembesh N; Sunbul R; Tonekaboni SH
BMC Neurol; 2015 Oct; 15():205. PubMed ID: 26471939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]